Case Study: Dock improves preeclampsia early detection and maternal care with LabCorp

Dock improves preeclampsia early detection with LabCorp’s 2nd/3rd trimester test in 23–35 weeks

Crystal Dock, an employee of LabCorp, faced the challenge of a recurring and severe case of preeclampsia during her second pregnancy. Her history with the condition and the subtle onset of symptoms made early detection critical to avoid life-threatening complications for both her and her baby.

LabCorp offers comprehensive preeclampsia testing solutions, including a first-trimester screening to assess risk and an FDA-cleared second/third trimester test for prognostic confirmation in hospitalized patients. While the case study does not specify that Crystal herself used these tests, it highlights LabCorp's role in providing these vital tools to help healthcare providers make timely decisions. The broader impact of LabCorp's services is improved early detection and risk assessment for this serious condition, which is a leading cause of maternal illness and death.

Dock